GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synthaverse SA (WAR:SVE) » Definitions » EV-to-EBITDA

Synthaverse (WAR:SVE) EV-to-EBITDA : 27.98 (As of May. 30, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Synthaverse EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Synthaverse's enterprise value is zł437.32 Mil. Synthaverse's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was zł15.63 Mil. Therefore, Synthaverse's EV-to-EBITDA for today is 27.98.

The historical rank and industry rank for Synthaverse's EV-to-EBITDA or its related term are showing as below:

WAR:SVE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6723.45   Med: 21.85   Max: 145.04
Current: 27.99

During the past 13 years, the highest EV-to-EBITDA of Synthaverse was 145.04. The lowest was -6723.45. And the median was 21.85.

WAR:SVE's EV-to-EBITDA is ranked worse than
77.26% of 497 companies
in the Biotechnology industry
Industry Median: 8.25 vs WAR:SVE: 27.99

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-30), Synthaverse's stock price is zł5.11. Synthaverse's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was zł0.064. Therefore, Synthaverse's PE Ratio (TTM) for today is 79.84.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Synthaverse EV-to-EBITDA Historical Data

The historical data trend for Synthaverse's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synthaverse EV-to-EBITDA Chart

Synthaverse Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.95 48.30 20.17 25.28 24.78

Synthaverse Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.31 24.78 26.38 37.10 24.33

Competitive Comparison of Synthaverse's EV-to-EBITDA

For the Biotechnology subindustry, Synthaverse's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synthaverse's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synthaverse's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Synthaverse's EV-to-EBITDA falls into.


;
;

Synthaverse EV-to-EBITDA Calculation

Synthaverse's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=437.321/15.627
=27.98

Synthaverse's current Enterprise Value is zł437.32 Mil.
Synthaverse's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł15.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Synthaverse  (WAR:SVE) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Synthaverse's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=5.11/0.064
=79.84

Synthaverse's share price for today is zł5.11.
Synthaverse's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.064.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Synthaverse EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Synthaverse's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Synthaverse Business Description

Traded in Other Exchanges
N/A
Address
10, Uniwersytecka street, Lublin, POL, 20-029
Synthaverse SA is a global pharmaceutical company. Its goal is to provide the best, innovative and unique solutions for medicine. Its work is based on scientific and health knowledge. Along with its expert approach, it allows the company to create reliable and unique products. It manufactures one of the few drugs used internationally in the oncological immunotherapy of bladder cancer.

Synthaverse Headlines

No Headlines